Maternal samples were assessed from 96 women enrolled in Pediatric AIDS Clinical Trials Group protocol 076 to determine the prevalence of human immunodeficiency virus type 1 (HIV-1) genotypic zidovudine resistance at entry, if zidovudine resistance developed on study, and the role of zidovudine resistance in vertical transmission of HIV-1 despite zidovudine therapy. Low and high levels of genotypic resistance were assessed by differential hybridization, oligoligation, or direct sequencing of plasma HIV-1 RNA for codons K70R and T215Y/F. None of the women had high-level genotypic resistance to zidovudine at study entry or delivery. For low-level zidovudine resistance, the 95% confidence intervals were 0.3% -6.8% for baseline prevalence and 0.3% -14% for delivery incidence. Low-level zidovudine resistance, adjusted for plasma viral RNA level at delivery, was not strongly associated with an increase in vertical transmission risk (odds ratio, 4.8; 95% confidence interval, 0.2 -131; P Å .35).
The Pediatric AIDS Clinical Trials Group (ACTG) protocol maternal plasma specimens drawn before the start of study 076 study demonstrated that zidovudine dramatically reduced treatment and at the time of delivery for the presence of specific the risk of maternal-infant transmission of human immunodemutations in HIV-1 pol, which represented genotypic zidovuficiency virus type 1 (HIV-1) from 22.6% to 7.6% [1, 2] . The dine resistance at either low levels (e.g., codon 70 [K70R; infrequent failure of zidovudine therapy to prevent vertical lysine to arginine]) or high levels (e.g., codon 215 [T215Y/F; transmission in some pregnant women may have been due to threonine to tyrosine or phenylalanine]) [3 -5] . These two cotransmission occurring before initiation of zidovudine therapy, don mutations were chosen because after prolonged zidovudine maternal infection with zidovudine-resistant strains of virus, or therapy, there is an ordered pattern to the development of genoother obstetric or maternal factors antepartum or intrapartum [2] . typic zidovudine resistance that is moderately correlated with To address the potential importance of maternal infection decreasing viral phenotypic susceptibility to zidovudine [5, 6] . with zidovudine-resistant strains of virus, we assayed stored For example, the development of the first mutation at codon 70 has been associated with little effect on the phenotypic susceptibility to zidovudine but nevertheless may be associated with a rise in viral RNA level [7] , while the later development JID 1998; 177 (March) from the uniform distribution to each nontransmitter who had an zidovudine resistance by the time of delivery; and fourth, the entry or delivery specimen available and selecting the subject if association of genotypic zidovudine resistance at delivery with the uniform random number was õ0.5.
risk of transmission despite zidovudine therapy.
To assess the influence of prior zidovudine therapy on the prevalence of genotypic zidovudine resistance at study entry, we included all eligible women, regardless of transmission status, in
Materials and Methods
either the zidovudine (n Å 12, of which 11 had an entry plasma Study design. Pediatric ACTG protocol 076 was a randomized, specimen) or the placebo arm (n Å 7, all of which had an entry double-blind, placebo-controlled trial of zidovudine to reduce maplasma specimen) who reported having received zidovudine therternal-infant HIV-1 transmission [1] . HIV-infected pregnant apy before study entry. Of the 11 assessable women in the zidovuwomen who had CD4 cell counts ú200/mL and no indications for dine arm who reported prior zidovudine therapy, 1 woman transantiretroviral therapy were enrolled between 14 and 34 weeks of mitted, 8 did not transmit, and 2 were of indeterminate transmission gestation, starting in April 1991. The study was closed to new status; by chance, 6 of the 8 nontransmitters were also included enrollment and unblinded in February 1994, when the first interim in the random sample described above. efficacy analysis found a two-thirds reduction in transmission rate In summary, a total of 96 women were assessed (table 1) : 85 in the zidovudine arm [1] . All women who were randomized by eligible women with known transmission status selected from the 20 December 1993 and had delivered by 4 January 1994, 6 weeks zidovudine arm (of which 1 transmitter and 6 nontransmitters rebefore unblinding of the study, were eligible for inclusion in the ported prior zidovudine therapy) and all 11 additional eligible but resistance substudy. Eligible subjects were considered assessable unselected women in either arm who reported prior zidovudine if a plasma specimen was available for analysis and evaluable therapy. if an HIV-1 reverse transcription-polymerase chain reaction Genotypic resistance. Genotypic resistance analysis of (RT-PCR)-amplified product was obtained from the plasma for plasma-associated HIV-1 RNA pol by differential hybridization of genotyping. Vertical transmission was defined by laboratory assays RT-PCR-amplified products was done as previously described for HIV-1 or if a condition considered to define the presence of [12] . If hybridization was indeterminate, RT-PCR products were AIDS was noted [2, 10] .
either detected by an EIA modification of the oligoligase detection To determine the prevalence of genotypic zidovudine resistance reaction assay [13] or sequenced directly by use of overlapping at study entry, development of resistance during the study, and internal primers, Taq polymerase, and dye-labeled dideoxy-termithe association of resistance with the risk of transmission despite nators (Applied Biosystems, Foster City, CA) or both. All sezidovudine therapy, we included all eligible women in the zidovuquences were proofread manually and aligned with SF2 as a condine arm who transmitted (n Å 15, of which only 12 had an entry sensus sequence. Genotypic assays were done blinded to treatment plasma specimen and 12 had a delivery plasma specimen available) assignment and infant infection status. and a random sample of women in the zidovudine arm who did HIV-1 RNA level and CD4 cell count. The two assays used for not transmit (n Å 183, of which 154 had an entry plasma specimen measuring the HIV-1 RNA level in plasma (RNA copies per milliliter) and 151 had a delivery plasma specimen available). The size of were the branched DNA (bDNA) assay (Quantiplex; Chiron, Emthe random sample was set at 72 nontransmitters to give Ç75% eryville, CA) and the RT-PCR amplification assay (Amplicor HIV statistical power (two-sided .05-level test) to detect an 8-fold
Monitor; Roche Molecular Systems, Branchburg, NJ), for which the greater risk of transmission among women who had genotypic experimental details are reported elsewhere [2] . The CD4 cell count zidovudine resistance at delivery compared with that among per microliter was measured by flow cytometry [2] . women who did not have resistance on the basis of an expected Statistical analysis. The genotypic zidovudine resistance rebaseline prevalence of genotypic zidovudine resistance in the study sults for each codon were reported as an ordered categorical varicohort of 10% [11] . The random sample was selected by assigning able reflecting the ratio of mutant to wild type virus: all wild type, wild type greater than mutant, mutant equal to wild type, mutant a computer-generated pseudorandom number between 0 and 1 NOTE. Assessed, subjects with plasma specimen available; evaluable, reverse transcription -polymerase chain reaction -amplified product obtained from plasma for genotyping.
* Specimens were available from 11 transmitters at both entry and delivery and 1 each from entry or delivery. † 11 subjects were assessed from zidovudine arm and 7 from placebo arm; 7 of 11 subjects from zidovudine arm are also counted in columns 1 and 2 because they were included in random sample used to assess other 3 objectives of substudy.
greater than wild type, or all mutant. Since so few women had Median CD4 cell counts and plasma HIV RNA levels among women with evaluable versus inevaluable specimens were comany evidence of genotypic resistance, in this analysis the data were dichotomized into two categories, wild type versus mutant, pared by the two-sample Wilcoxon test. in which the mutant category was obtained by collapsing the four categories indicating the presence of any mutant virus.
Results
The prevalence of mutations at entry among all 198 women randomized to the zidovudine arm was estimated by use of a Subject characteristics. The baseline characteristics of the weighted average of the proportions of transmitters and nontrans-85 assessable subjects chosen from the zidovudine treatment mitters with a mutation at study entry, weighted by the zidovudine arm for the resistance substudy did not differ significantly from arm transmission rate (7.6%) and its complement (92.4%), respecthose of the entire 198-subject zidovudine arm (table 2). The tively [14] . The proportion of women in the zidovudine arm who substudy subjects were mostly antiretroviral-inexperienced were wild type at entry but developed genotypic zidovudine resis-(91.8%) and relatively immunocompetent (median CD4 cell tance at delivery was estimated similarly on the basis of the subgroup of women in the zidovudine arm who had evaluable results count, ú550/mL). At baseline, the 19 eligible women who at both entry and delivery and who were wild type at study entry. reported prior zidovudine therapy had similar plasma HIV RNA Approximate 95% confidence intervals for each of these estimates levels by both bDNA and RT-PCR assays but lower CD4 cell and for the prevalence of mutations among women who reported counts compared with the entire Pediatric ACTG protocol 076 prior zidovudine therapy were calculated by use of the binomial cohort (data not shown).
distribution (with adjustment for finite population sampling in the Prevalence of genotypic zidovudine resistance at study entry.
case of the first two estimates) [14] [15] [16] .
Only 1 (1.6%) of 61 evaluable women sampled from the zidoBecause plasma viral RNA level (determined by RT-PCR) at vudine arm (table 3) and 1 (6.7%) of 15 evaluable women from delivery was a significant predictor of transmission risk in this either the zidovudine or placebo arms who reported any prior cohort [2] , the association between presence of a mutation at delivzidovudine therapy ( women had evidence of a codon T215Y/F mutation at study phan) mutation (data not shown). On the basis of the data in table 3, the estimated percentage of all women randomized to the zidovudine arm (n Å 198) who had a codon K70R mutation at entry was 0.8% (95% confidence interval, 0.3 -6.8). Also, Association of resistance with the risk of transmission despite zidovudine therapy. Among women with evaluable rewith Ç95% confidence, at most 5.6% of all women in the zidovudine arm could have had a codon T215Y/F mutation at sults at codon 70, only 2 (4.3%) of 47 had a codon K70R mutation at delivery (table 5); 1 of the women transmitted but entry.
For all women who reported any zidovudine experience at the other did not (table 6) . None of the women exhibited any evidence of a codon T215Y/F mutation at delivery. The 1 study entry (n Å 19), the estimated prevalence (with Ç95% confidence) of low-level zidovudine resistance was at most woman who transmitted virus to her infant had a plasma viral RNA level above the 75th percentile by both bDNA and 32.0% and the estimated prevalence for high-level resistance was at most 18.1% (table 4) .
Women with inevaluable results had significantly higher NOTE. RT-PCR, reverse transcription -polymerase chain reaction; bDNA, branched DNA. WT, wild type; Mut, mutant; Mix, mixture. * Infant had M41, K70R, K70, T215 genotypes identified in plasma obtained at 5th week after birth. † Infant had negative HIV-1 culture at 14 weeks, but no other culture, HIV-1 DNA PCR amplification, or serology results available. Last clinic visit was at 13 months of age; no AIDS-defining diagnoses or HIV-1 -related symptoms were reported up to that point. Data are insufficient to classify infant as infected or uninfected [2, 10] .
RT-PCR assays and an entry CD4 cell count below the 25th mother as well as for prophylaxis of perinatal transmission [18] . Nevertheless, some HIV-1 -infected pregnant women percentile in the zidovudine arm (table 2 and table 6 ). Interestingly, her baseline viral genotype was a codon K70R mutant may choose to minimize their exposure to these agents and use zidovudine monotherapy to decrease their risk of vertical despite reporting no prior zidovudine therapy. Her infected infant had HIV-1 cultured from peripheral blood mononuclear transmission. As such, it is important to document whether the use of zidovudine monotherapy during pregnancy presents any cells and HIV-1 RNA detected by the RT-PCR assay from a plasma specimen obtained 5 weeks postpartum but neither risk for the development of zidovudine resistance and whether the risk of vertical transmission is increased if such resistance recovery of infectious virus from peripheral blood mononuclear cells nor detectable viral RNA in plasma obtained at delivery.
occurs. Our data are reassuring in this regard. Although vertical transmission of HIV-1 by women taking A mixture of codon K70 and K70R viral genotypes was detected in the infant's 5-week-postpartum plasma specimen.
zidovudine during pregnancy has been reported [1, 2, 19 -21] , this is the first study to define the differential risk of vertical Despite the small sample size, plasma HIV-1 RNA level at delivery (determined by RT-PCR) was a statistically significant transmission of viruses that have low-level genotypic resistance to zidovudine. We showed that the development of genotypic predictor of transmission risk, with an adjusted odds ratio of 4.0 (95% confidence interval, 1.1 -14.6; P Å .04) for every resistance to zidovudine by the time of delivery was unusual in HIV-1 -infected pregnant women with ú200 CD4 cells/mL 5-fold difference in viral RNA level. However, the presence of a codon K70R mutation at delivery was not associated with when zidovudine was taken according to the Pediatric ACTG protocol 076 study schedule, thus supporting further the shorta statistically significant increase in transmission risk, with an adjusted odds ratio of 4.8 (95% confidence interval, 0.2 -131; term safety of zidovudine in pregnancy [22] . Moreover, the infrequent failure of zidovudine therapy to prevent transmission P Å .35) after controlling for plasma HIV-1 RNA level at delivery.
of HIV-1 to some infants was not explained by the presence of maternal virus with genotypic zidovudine resistance, given that our sample size was based on having adequate statistical Discussion power to detect an 8-fold-greater risk of transmission among women who had genotypic zidovudine resistance at delivery Now that combination antiretroviral therapy has become the standard of care for the treatment of HIV-1 infection, it is compared with the risk among women who did not have resistance. As such, an association of genotypic resistance with a likely that zidovudine monotherapy during pregnancy will become less frequent as zidovudine is used in combination with smaller increased risk of transmission could not be completely ruled out. other antiretroviral agents for the treatment of the pregnant / 9d41$$mr20
12-30-97 17:50:43 jinfa UC: J Infect
The level of genotypic zidovudine resistance at study entry suggested intrapartum infection. Although the infant's 5-weekpostpartum plasma HIV-1 RNA genotype was similar to the for subjects reporting little or no previous zidovudine therapy was very low. High-level genotypic resistance (codon T215Y/F mother's plasma viral RNA genotype pattern at delivery, we were unable to distinguish between acquisition of the mutant mutation) was not detected and low-level genotypic resistance (codon K70R mutation) was observed in only 1 (1.6%) of virus from the mother intrapartum or development of the mutant virus, because the infant received protocol-mandated zido-61 evaluable women randomly sampled from the zidovudine therapy arm. The level of genotypic resistance at entry in vudine during the 6-week-postpartum period. There were substantial numbers of inevaluable women bewomen reporting any prior zidovudine experience was also relatively low, albeit Ç4-fold higher than for the zidovudine arm cause an RT-PCR product was not obtained for genotyping from all plasma specimens, thus limiting the power to detect alone. Evidence of a high-level resistance codon T215Y/F mutation was absent, while the low-level resistance codon K70R mutaless than a very strong association between zidovudine resistance and transmission of HIV-1. Nevertheless, the high CD4 tion was detected in 1 (6.7%) of 15 evaluable women from both the zidovudine and placebo arms. These estimates are similar to cell count and low plasma viral RNA level for these inevaluable women suggest that the frequency of mutations would be simithe £10% prevalence of zidovudine resistance reported for incident HIV-1 infection between 1991 and 1994 [11, 23, 24] . lar or even lower than for the evaluable subjects [26, 27] . Despite the small sample size for this study, the data suggest The presence of a codon T215C mutation at study entry from 1 zidovudine-naive woman in the zidovudine treatment that maternal viral genotypic zidovudine resistance was not responsible for infrequent zidovudine failure of infant prophyarm is of unknown significance. However, a codon L210W mutation in the zidovudine-experienced woman with the codon laxis in the Pediatric ACTG protocol 076 study. Presumably, the timing of transmission or other obstetric or maternal factors T215D mutation indicates that a reversion intermediate form of the virus was likely present at study entry in 1 if not both antepartum, intrapartum, or postpartum were responsible for the minority failure of zidovudine to prevent vertical transmisof these women [25] . The viruses from each of these 2 women were codon M41 wild type (data not shown).
sion [28 -32] and are being evaluated by the ACTG 076 protocol team. There was very little evidence that genotypic zidovudine resistance developed by the time of delivery. This result is not
In conclusion, there was little evidence for a strong association between HIV-1 genotypic zidovudine resistance and maunexpected, given the relatively short duration of zidovudine exposure during pregnancy, low median viral RNA level, and ternal-infant transmission in this study of mostly zidovudinenaive women with a median CD4 cell count of ú540/mL. The high median CD4 cell count for the study subjects [2, 26, 27] . Although our results are applicable to HIV-infected women high-level zidovudine resistance codon T215Y/F mutation was not observed in this study, and the presence of a codon K70R with CD4 cell counts ú200/mL, the use of zidovudine in a population of pregnant women with more advanced HIV infecmutation at delivery was not associated with a significantly increased risk of transmission. Therefore, other explanations tion may be associated with resistance and possible failure of zidovudine therapy to prevent transmission. must be sought for the infrequent failure of zidovudine therapy to prevent vertical transmission of HIV-1 in infected women There was little evidence of a strong association between resistance at delivery and transmission risk. Despite reports of who have little zidovudine experience and a relatively intact immune system. Our observations do not, however, preclude vertical transmission of zidovudine-resistant virus [20] , only 1 woman who transmitted HIV-1 had the codon K70R mutation.
resistance as a mechanism for the failure of zidovudine to prevent vertical transmission of virus in pregnant women with The estimated odds ratio for transmission risk was 4.8 for the codon 70 mutation, but it was not statistically significant (P Å more advanced HIV-1 infection and more extensive zidovudine experience. .35), with wide confidence intervals, because of the small sample size and low prevalence, which enabled us to detect only
